Windtree Therapeutics, Inc. EV/FCF

EV/FCF of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of Windtree Therapeutics, Inc. is -5.49 (as of December 30, 2019)
  • EV/FCF for the quarter ending December 30, 2019 was -5.49 (a -15.23% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF increased by 326.93%
  • Annual EV/FCF for 2019 was -5.49 (a 326.93% increase from previous year)
  • Annual EV/FCF for 2018 was -1.29 (a -19.13% decrease from previous year)
  • Annual EV/FCF for 2017 was -1.59 (a 79.45% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Windtree Therapeutics, Inc.

Most recent EV/FCFof WINT including historical data for past 10 years.

Interactive Chart of EV/FCF of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -5.49 -6.48 -6.59 -5.49
2018 -1.29 -2.15 -2.2 -1.58 -1.29
2017 -1.59 -1.23 -0.91 -0.85 -1.59
2016 -0.89 -0.99 -0.61 -0.27 -0.89
2015 -0.2 -0.29 -1.36 -2.16 -0.2
2014 -1.77 -2.88 -2.52 -3.01 -1.77
2013 -1.38 -2.33 -1.39 -2.11 -1.38
2012 -1.68
2011 -1.51 -0.27 -1.27

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.